Impact of genotypic susceptibility score on cART outcomes during primary HIV infection

Andrea Giacomelli, Massimiliano Fabbiani, Ilaria De Benedetto, Silvia Nozza, Emanuele Focà, Benedetto M. Celesia, Giulia Marchetti, Cristina Mussini, Andrea Antinori, Gabriella d’Ettorre, Giordano Madeddu, Alessandra Bandera, Antonio Muscatello, Stefano Rusconi

Research output: Contribution to journalArticlepeer-review


To assess the impact of genotypic susceptibility score (GSS) on combined antiretroviral therapy (cART) outcomes during primary HIV infection (PHI) we retrospectively enrolled patients with PHI diagnosed between 2008 and 2015 at 9/24 Italian Network ACuTe HIV InfectiON centers. One hundred-seventy-six patients were enrolled. Of these, 55 (32.9%) patients started with more than three drugs and 11 (7.2%) started with a GSS < 3. Regimen's GSS (per 1 point increase) (adjusted odds ratio [aOR], 4.82; 95% confidence interval [CI], 1.62-14.28; P =.005) and baseline HIV-RNA (per 1 log10 increase) (aOR, 2.02; 95% CI, 1.09-3.73; P =.025) resulted associated with early cART initiation. In conclusion, regimen's GSS resulted to be associated to the time to cART initiation during PHI.

Original languageEnglish
Pages (from-to)1-15
Number of pages15
JournalJournal of Medical Virology
Publication statusE-pub ahead of print - Jun 14 2019


  • GSS
  • HIV
  • primary HIV

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases


Dive into the research topics of 'Impact of genotypic susceptibility score on cART outcomes during primary HIV infection'. Together they form a unique fingerprint.

Cite this